DUBLIN - May 28, 2018 - Medtronic plc (MDT), the global leader in medical technology, today announced real-world clinical outcomes for the MiniMed(TM) 670G system, which is being used by more than 180 ...

Medtronic plcMDT commercially launched MiniMed 670G system, a Hybrid Closed Loop insulin delivery system for Type I diabetic patients. This happened following the U.S. FDA approval late last year.

Editor’s Note: A few weeks ago, a Type 1 diabetes patient authored a blog post about why she didn’t want to switch to Medtronic’s MiniMed 670G billed as the industry’s first hybrid closed-loop insulin ...

Medtronic's MiniMed 670G could reduce the burden on Type 1 diabetes patients, as well as slow diabetes progression by keeping blood glucose levels on target. There are about 1.25 million Americans ...

Medtronic says real-world data show its MiniMed 670G glucose management system increased time in range for people with diabetes. Medtronic has announced clinical outcomes for the MiniMed 670G system, ...

Medtronic touted new clinical data from its growing base of MiniMed 670G insulin-pump users, noting on Tuesday that people who used the pump's most advanced features kept their blood sugar levels ...

DUBLIN and VIENNA - February 15, 2018 - Medtronic plc (MDT), the global leader in medical technology, today announced that new data from its at-home pediatric study of the MiniMed(TM) 670G system in ...

The MiniMed™ 670G System Features the Company's Most Advanced SmartGuard™ Algorithm BRAMPTON, ON, Oct. 10, 2018 /CNW/ - Medtronic of Canada Ltd., a subsidiary of Medtronic plc (NYSE: MDT), today ...